File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes

TitleGlycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes
Authors
Issue Date1-Nov-2024
PublisherAlimentary Pharmacology & Therapeutics
Citation
Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver-related mortality in patients with diabetes, 2024, v. 60, n. 10, p. 1398-1408 How to Cite?
Abstract

Background: Optimal glycaemic control has well-established health benefits in patients with diabetes mellitus (DM). It is uncertain whether optimal glycaemic control can benefit liver-related outcomes.

Aims: To examine the association of optimal glycaemic control with hepatocellular carcinoma (HCC) and liver-related mortality.

Methods: In a population-based cohort, we identified patients with newly diagnosed DM between 2001 and 2016 in Hong Kong. Optimal glycaemic control was defined as mean haemoglobin A1c (HbA1c) <7% during the 3-year lead-in period after DM diagnosis. By applying propensity score matching to balance covariates, we analysed glycaemic control via competing risk models with outcomes of interest being HCC and liver-related mortality.

Results: We identified 146,430 patients (52.2% males, mean age 61.4 ± 11.8 years). During a median follow-up duration of 7.0 years, 1099 (0.8%) and 978 (0.7%) patients developed HCC and liver-related deaths. Optimal glycaemic control, when compared to suboptimal glycaemic control, was associated with reduced risk of HCC (subdistribution hazard ratio [SHR] 0.70, 95% CI 0.61-0.79). The risk of HCC increased with incremental HbA1c increases beyond >7% (SHR 1.29-1.71). Significant associations with HCC were also found irrespective of age (SHR 0.54-0.80), sex (SHR 0.68-0.69), BMI <25 or ≥25 kg/m2 (SHR 0.63-0.75), smoking (SHR 0.61-0.72), hepatic steatosis (SHR 0.67-0.68) and aspirin/statin/metformin use (SHR 0.67-0.75). A lower risk of liver-related mortality in relation to optimal glycaemic control was also observed (SHR 0.70, 95% CI 0.61-0.80).

Conclusions: Glycaemic control is an independent risk factor for HCC and liver-related mortality, and should be incorporated into oncoprotective strategies in the general DM population.


Persistent Identifierhttp://hdl.handle.net/10722/350827
ISSN
2023 Impact Factor: 6.6
2023 SCImago Journal Rankings: 2.794

 

DC FieldValueLanguage
dc.contributor.authorMao, Xianhua-
dc.contributor.authorCheung, Ka-Shing-
dc.contributor.authorTan, Jing-Tong-
dc.contributor.authorMak, Lung-Yi-
dc.contributor.authorLee, Chi-Ho-
dc.contributor.authorChiang, Chi-Leung-
dc.contributor.authorCheng, Ho-Ming-
dc.contributor.authorHui, Rex Wan-Hin-
dc.contributor.authorLeung, Wai K-
dc.contributor.authorYuen, Man-Fung-
dc.contributor.authorSeto, Wai-Kay-
dc.date.accessioned2024-11-03T00:30:39Z-
dc.date.available2024-11-03T00:30:39Z-
dc.date.issued2024-11-01-
dc.identifier.citationGlycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver-related mortality in patients with diabetes, 2024, v. 60, n. 10, p. 1398-1408-
dc.identifier.issn0269-2813-
dc.identifier.urihttp://hdl.handle.net/10722/350827-
dc.description.abstract<p><strong>Background: </strong>Optimal glycaemic control has well-established health benefits in patients with diabetes mellitus (DM). It is uncertain whether optimal glycaemic control can benefit liver-related outcomes.</p><p><strong>Aims: </strong>To examine the association of optimal glycaemic control with hepatocellular carcinoma (HCC) and liver-related mortality.</p><p><strong>Methods: </strong>In a population-based cohort, we identified patients with newly diagnosed DM between 2001 and 2016 in Hong Kong. Optimal glycaemic control was defined as mean haemoglobin A1c (HbA1c) <7% during the 3-year lead-in period after DM diagnosis. By applying propensity score matching to balance covariates, we analysed glycaemic control via competing risk models with outcomes of interest being HCC and liver-related mortality.</p><p><strong>Results: </strong>We identified 146,430 patients (52.2% males, mean age 61.4 ± 11.8 years). During a median follow-up duration of 7.0 years, 1099 (0.8%) and 978 (0.7%) patients developed HCC and liver-related deaths. Optimal glycaemic control, when compared to suboptimal glycaemic control, was associated with reduced risk of HCC (subdistribution hazard ratio [SHR] 0.70, 95% CI 0.61-0.79). The risk of HCC increased with incremental HbA1c increases beyond >7% (SHR 1.29-1.71). Significant associations with HCC were also found irrespective of age (SHR 0.54-0.80), sex (SHR 0.68-0.69), BMI <25 or ≥25 kg/m<sup>2</sup> (SHR 0.63-0.75), smoking (SHR 0.61-0.72), hepatic steatosis (SHR 0.67-0.68) and aspirin/statin/metformin use (SHR 0.67-0.75). A lower risk of liver-related mortality in relation to optimal glycaemic control was also observed (SHR 0.70, 95% CI 0.61-0.80).</p><p><strong>Conclusions: </strong>Glycaemic control is an independent risk factor for HCC and liver-related mortality, and should be incorporated into oncoprotective strategies in the general DM population.</p>-
dc.languageeng-
dc.publisherAlimentary Pharmacology & Therapeutics-
dc.relation.ispartofGlycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver-related mortality in patients with diabetes-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleGlycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes-
dc.typeArticle-
dc.identifier.doi10.1111/apt.18254-
dc.identifier.volume60-
dc.identifier.issue10-
dc.identifier.spage1398-
dc.identifier.epage1408-
dc.identifier.eissn1365-2036-
dc.identifier.issnl0269-2813-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats